Skip to content

Nuvalent, Inc. NUVL Accrued expenses and other liabilities

Accrued expenses and other liabilities at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.72B+21.5%

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s accrued expenses and other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s accrued expenses and other liabilities?
Nuvalent, Inc. (NUVL) reported accrued expenses and other liabilities of $58.92M in Q1 2026.
How has Nuvalent, Inc.'s accrued expenses and other liabilities changed year-over-year?
Nuvalent, Inc.'s accrued expenses and other liabilities increased by 20.6% year-over-year, from $48.87M to $58.92M.
What is the long-term trend for Nuvalent, Inc.'s accrued expenses and other liabilities?
Over 2 years (2020 to 2025), Nuvalent, Inc.'s accrued expenses and other liabilities has grown at a 621.8% compound annual growth rate (CAGR), from $1.17M to $61.01M.